Medgold Resources is pleased to announce that it has arranged, subject to TSX Venture Exchange approval, a non-brokered private placement financing of up to 20 million units at $0.06 per unit, for proceeds of up to $1.2 million. Each unit will consist of one common share and one-half of a warrant. Each whole warrant will entitle the holder to purchase one additional common share of the Company at $0.10 for one year from [...]
Medgold Resources announces that its Board of Directors has determined that it is in the best interests of the Company to amend the exercise price of private placement warrants issued earlier this year. Accordingly, subject to TSXV acceptance, the exercise price of outstanding warrants entitling the holders to purchase a total of 6,500,000 shares has been reduced from $0.15 per share to $0.06 per share. The expiry date of [...]
Medgold Resources is pleased to announce that recent sampling at its wholly-owned Boticas project has identified a significant new zone of gold mineralization called Limarinho South. Recent sampling at the new zone returned sample results from 0.05 g/t Au up to 6.55 g/t Au in 14 rock samples. Selective grab samples gave grades of 6.55 g/t, 4.98 g/t and 0.15 g/t Au, and a channel-chip sample yielded a length-weighted [...]
Medgold is pleased to announce that it has been awarded the Boticas exploration licence in northern Portugal by the Direção-Geral de Energia e Geologia (DGEG) of Portugal. Dan James, the President of the Company, commented: "We're delighted that the Boticas licence has been awarded and I would like to thank the DGEG and the Portuguese government for their continued support. We now plan to fast-track the project to [...]
Medgold Resources is pleased to report excellent first-pass sampling results from recent work at its wholly-owned Vila de Rei gold project in central Portugal. The project covers 40 line km of a regional structure which is known to contain multiple gold-bearing zones. Preliminary exploration at the Pampilhal prospect has outlined highly anomalous gold mineralisation associated with silicification over a 2.4 km by 1.3 km [...]
Medgold Resources is pleased to announce results of recently completed exploration at its wholly-owned Pietratonda licence in the Colline Metallifere of Central Italy. Dan James, President of Medgold, said, "The current work has outlined a large gold-antimony anomaly and highlights the exciting potential of the Colline Metallifere of Central Italy. We believe that the gold mineralization is controlled by high-angle [...]
Medgold is pleased to advise that it has closed its previously announced $975,000 convertible debenture private placement. The debentures are convertible into 6,500,000 common shares of the Company for two years from closing at the rate of $0.15 per share. The debenture holder has also been issued warrants to purchase up to 6,500,000 additional common shares at $0.15 per share, exercisable for one year from the date of [...]
Medgold is pleased to announce that it has now completed the application process and paid all relevant taxes for three contiguous gold exploration permits covering 79 square kilometres in southern Galicia. Dan James, President of Medgold, said, "This transaction marks our entry into Spain. We believe the entire region is highly prospective, already hosting several advanced gold projects. We have identified a 14 km linear [...]
Medgold Resources is pleased to announce that it has been issued the highly prospective 300 square kilometer Vila de Rei gold exploration licence in central Portugal. Licence located in highly prospective central Portuguese region. High-grade rock grab samples, from trace up to 24.7 g/t Au. Over 40 km of structure identified already. Exploration work to commence immediately over key prospect areas. Acquisition marks [...]
Medgold is pleased to announce that it has arranged, subject to Exchange approval, a $975,000 non-brokered private placement financing of debentures which are convertible into 6,500,000 common shares of the Company at the rate of $0.15 per share. The debentures will bear interest at the rate of 8% per annum and are convertible into shares for a period of up to two years from closing of the financing. The debenture holders [...]
+1700,00 %
-55,56 %
